UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition

Journal for immunotherapy of cancer, 2020-06, Vol.8 (1), p.e000842

2020

Volltextzugriff (PDF)

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma

Journal for immunotherapy of cancer, 2020-04, Vol.8 (1), p.e000234

2020

Volltextzugriff (PDF)

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.33-16, Article 33

2019

Volltextzugriff (PDF)

Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma

Clinical cancer research, 2018-12, Vol.24 (24), p.6236-6247

2018

Volltextzugriff (PDF)

Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells

Clinical cancer research, 2020-07, Vol.26 (13), p.3384-3396

2020

Volltextzugriff (PDF)

Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma

Melanoma research, 2022-10, Vol.32 (5), p.324-333

2022

Volltextzugriff (PDF)

High-Parameter Single-Cell Analysis

Annual review of analytical chemistry (Palo Alto, Calif.), 2019-06, Vol.12 (1), p.411-430

2019

Volltextzugriff (PDF)

Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes

JCI insight, 2020-06, Vol.5 (11)

2020

Volltextzugriff (PDF)

Abstract PO-007: The Class I/IV HDAC Inhibitor Mocetinostat Augments Anti-Tumor Immune Responses in Melanoma Patients

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (23_Supplement), p.PO-007-PO-007

2020

Volltextzugriff (PDF)

Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10052-10052

2020

Volltextzugriff (PDF)

Rapid Expansion of Highly Functional Antigen-Specific T cells from Melanoma Patients by Nanoscale Artificial Antigen Presenting Cells

Clinical cancer research, 2020-04, Vol.26 (13), p.3384-3396

2020

Volltextzugriff (PDF)

Abstract PO030: A Novel T-cell Population Expressing the Ectoenzymes CD38 and CD39 is Associated with Melanoma Patient Non-Response to Immunotherapy

Cancer immunology research, 2021-02, Vol.9 (2_Supplement), p.PO030-PO030

2021

Volltextzugriff (PDF)

Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT032-CT032

2020

Volltextzugriff (PDF)

A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3092-3092

2020

Volltextzugriff (PDF)

Abstract 2564: Histone deacetylase 6 is a novel target for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2564-2564

2014

Volltextzugriff (PDF)

An efficient low cost method for gene transfer to T lymphocytes

PloS one, 2013-03, Vol.8 (3), p.e60298

2013

Volltextzugriff (PDF)

Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function

Molecular immunology, 2015-02, Vol.63 (2), p.579-585

2015

Volltextzugriff (PDF)

Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions

International reviews of immunology, 2011-10, Vol.30 (5-6), p.294-311

2011

Volltextzugriff (PDF)

High-dimension flow cytometry reveals comprehensive deviations in immunophenotypes associated with non-response to melanoma immunotherapies

The Journal of immunology (1950), 2019-05, Vol.202 (1_Supplement), p.194-194.21

2019

Volltextzugriff (PDF)

Association of changes in T regulatory cells (Treg) during nivolumab treatment with melanoma outcome

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3031-3031

2017

Volltextzugriff (PDF)

1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 2), p.A1754-A1754

2023

Volltextzugriff (PDF)

Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.100-100

2019

Volltextzugriff (PDF)

Abstract 1338: Novel implications of histone deacetylase 6 selective inhibition in melanoma T-cell immunotherapy

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1338-1338

2015

Volltextzugriff (PDF)

Proteomic and T cell biomarkers identify sensitivity and resistance to immunotherapy in cancer patients

Annals of oncology, 2017-10, Vol.28 Suppl 9, p.ix21

2017

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(34)
Dissertationen
(1)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma

Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells

Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma

High-Parameter Single-Cell Analysis

Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes

Abstract PO-007: The Class I/IV HDAC Inhibitor Mocetinostat Augments Anti-Tumor Immune Responses in Melanoma Patients

Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma

Rapid Expansion of Highly Functional Antigen-Specific T cells from Melanoma Patients by Nanoscale Artificial Antigen Presenting Cells

Abstract PO030: A Novel T-cell Population Expressing the Ectoenzymes CD38 and CD39 is Associated with Melanoma Patient Non-Response to Immunotherapy

Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies

A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab

Abstract 2564: Histone deacetylase 6 is a novel target for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination

An efficient low cost method for gene transfer to T lymphocytes

Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function

Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions

High-dimension flow cytometry reveals comprehensive deviations in immunophenotypes associated with non-response to melanoma immunotherapies

Association of changes in T regulatory cells (Treg) during nivolumab treatment with melanoma outcome

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab

Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition

Abstract 1338: Novel implications of histone deacetylase 6 selective inhibition in melanoma T-cell immunotherapy

Proteomic and T cell biomarkers identify sensitivity and resistance to immunotherapy in cancer patients

Suchergebnisse filtern